Polypharmacy as a risk factor for depressive symptoms in geriatric patients: an observational, cross-sectional study
DOI:
https://doi.org/10.30827/ars.v57i3.5330Keywords:
elderly, adverse drug effects, mental health, psychiatryAbstract
Aim: The aim of this study was to investigate the correlation between polypharmacy and depressive symptoms in hospitalized adults aged over 65 years.
Patients and methods: We obtained medical history and current treatment data from clinical records. We used the Abbreviated Mental Test Score (AMTS) to exclude patients with dementia. The Geriatric Depression Scale (GDS) was used assess depressive symptoms. Pearson and Spearman coefficients were used to determine the relationship between variables.
Results: A total of 206 individuals were included. The average number of medications taken by the individuals was 6.9 ± 2.7 and the average GDS score was 4.9 ± 3.4 points. Depressive symptoms (GDS score >5 points) were observed in 68 (33.0%) individuals. GDS score positively correlated with the number of medications used (R = 0.74; P = 0.0001), the number of chronic conditions (R = 0.78; P = 0.001), and pain complaints (Z = 7.94; P = 0.0001). A significant association between GDS score and the use of the following medications was observed: statins, cytostatic agents, corticosteroids, benzodiazepines, cardiac glycosides, non-steroidal anti-inflammatory drugs, muscle relaxants, non-psychotropic drugs with anticholinergic properties, and centrally acting analgesics (all P < 0.05).
Conclusions: Our study indicates that polypharmacy is positively correlated with the presence of depressive symptoms in geriatric patients. We identified a number of medications associated with a higher prevalence of depressive symptoms, however these relationships require further examination.
Downloads
References
European Commission; Directorate General for Economic and Financial Affairs. The 2015 Ageing Report: Underlying Assumptions and Projection Methodologies. European Economy. 2014.
Barua A, Ghosh MK, Kar N, Basilio MA. Prevalence of depressive disorders in the elderly. Ann Saudi Med. 2011;31(6):620-624.
Royal College of Psychiatrists; Faculty of Old Age. Who Cares Wins. Improving the outcome for older people admitted to the general hospital: guidelines for the development of liaison mental health services for older people. London. 2005.
Wiese BS. Geriatric depression: The use of antidepressants in the elderly. BCMJ. 2011;53:341-347.
Parker C. Psychiatric effects of drugs for other disorders. Medicine. 2012;40(12):691-695.
Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. 1972. Age Ageing. 2012;41 Suppl 3:iii35-40.
Sheikh J, Yesavage J. Geriatric Depression Scale: recent evidence and development of a shorter version. Clin Gerontol. 1986;5:165-173.
Liu CP, Leung DS, Chi I. Social functioning, polypharmacy and depression in older Chinese primary care patients. Aging Ment Health. 2011;15(6):732-741.
Antonelli Incalzi R, Corsonello A, Pedone C, Corica F, Carbonin P. Depression and drug utilization in an elderly population. Ther Clin Risk Manag. 2005;1:55-60.
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
Nobili A, Licata G, Salerno F, et al.. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67(5):507-519.
Gallagher P, Lang PO, Cherubini A, et al.. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011;67(11):1175-1188.
Marengoni A, Angleman S, Melis R, et al.. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430-439.
Spangenberg L, Forkmann T, Brahler E, Glaesmer H. The association of depression and multimorbidity in the elderly: implications for the assessment of depression. Psychogeriatrics. 2011;11(4):227-234.
Marazziti D, Mungai F, Vivarelli L, Presta S, Dell’Osso B. Pain and psychiatry: a critical analysis and pharmacological review. Clin Pract Epidemiol Ment Health. 2006;2:31.
Banks SM, Kerns RD. Explaining high rates of depression in chronic pain: A diathesis-stress framework. Psychol Bull 1996;119:95-110.
Abdulraheem IS. Polypharmacy: A Risk Factor for Geriatric Syndrome, Morbidity & Mortality. Aging Sci. 2013;1.
Nobili A, Pasina L, Tettamanti M, et al.. Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database. J Clin Pharm Ther. 2009;34(4):377-386.
Pirmohamed M, James S, Meakin S, et al.. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-19.
Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901-910.
Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123-132.
Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity. 2011;1:28-44.
Turjansk N, Lloyd GG. Psychiatric side-effects of medications: recent developments. . Adv Psychiatr Treat. 2011;11:58-70.
Pasina L, Djade CD, Lucca U, et al.. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging. 2013;30(2):103-112.
Drevets WC, Zarate CA, Jr., Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013;73(12):1156-1163.
Cheng JW, Rybak I. Use of digoxin for heart failure and atrial fibrillation in elderly patients. Am J Geriatr Pharmacother. 2010;8(5):419-427.
Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC. Depressogenic effects of medications: a review. Dialogues Clin Neurosci. 2011;13(1):109-125.
Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527-1537.
Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361-1367.
Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011;65(6):549-560.
Yang M, Moon C. Neurotoxicity of cancer chemotherapy. Neural Regen Res. 2013;8(17):1606-1614.
van Vliet P, van der Mast RC, van den Broek M, Westendorp RG, de Craen AJ. Use of benzodiazepines, depressive symptoms and cognitive function in old age. Int J Geriatr Psychiatry. 2009;24(5):500-508.
Sithamparanathan K, Sadera A, Leung L. Adverse effects of benzodiazepine use in elderly people: a meta-analysis. Int J Geriatr Psychiatry. 2012;7:107-111.
Swiger KJ, Manalac RJ, Blaha MJ, Blumenthal RS, Martin SS. Statins, mood, sleep, and physical function: a systematic review. Eur J Clin Pharmacol. 2014;70(12):1413-1422.
Ainiyet B, Rybakowski JK. Suicidal behaviour and lipid levels in unipolar and bipolar depression. Acta Neuropsychiatr. 2014;26(5):315-320.
Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf. 2007;30:195-201.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
